Amgen up after quarterly profit beat

Shares of Amgen AMGN.O rise nearly 1% to $286.50 in aftermarket trading

Drugmaker reports Q1 adj. profit per share of $4.90, beating estimates of $4.30

Company's quarterly revenue up 9% to $8.1 billion

Says U.S. FDA has lifted its clinical hold on an early-stage trial of an experimental weight-loss drug known as AMG 513

Reiterates annual adj. profit per share to be between $20 and $21.20; 2025 revenue to be in the range of $34.3 billion to $35.7 billion

Adds 2025 projection includes the estimated impact of implemented tariffs, but does not account for any tariff that could be implemented in the future, including potential sector-specific ones

Stock rose 9% YTD